STOCK TITAN

Syros Pharmaceuticals, Inc. - $SYRS STOCK NEWS

Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: $SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.

Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.

At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.

While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.

Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.

Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will host a webcast on June 25, 2024, from 11:00 a.m. to 12:30 p.m. ET to discuss higher-risk myelodysplastic syndrome (HR-MDS) and the potential of tamibarotene as a new frontline treatment for patients with RARA gene overexpression. Three medical experts will join Syros’ leadership to provide an overview of patient management, current and future treatment landscapes, and tamibarotene's opportunity. Syros is evaluating tamibarotene in pivotal Phase 3 SELECT-MDS-1 and Phase 2 SELECT-AML-1 trials, with pivotal data expected by mid-Q4 2024 and clinical activity and tolerability data by Q3 2024. The event will include presentations on HR-MDS disease overview, current therapies, trial outcomes, and tamibarotene’s mechanism of action.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
conferences
-
Rhea-AI Summary

Syros Pharmaceuticals (SYRS) reported its first-quarter 2024 financial results and provided a corporate update. The company highlighted passing an interim futility analysis in the Phase 3 SELECT-MDS-1 trial, with pivotal CR data expected by mid-Q4 2024. Additionally, the FDA granted Fast Track designation for Tamibarotene in unfit AML. Financially, Syros recorded no revenue compared to $3 million in Q1 2023, and a net loss of $3.7 million, significantly reduced from $23.8 million the previous year. R&D expenses were $24.7 million, down from $28.8 million, while G&A expenses also decreased from $7.4 million to $6.3 million. The company’s cash position was $108.3 million as of March 31, 2024, sufficient to fund operations into Q3 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
-
Rhea-AI Summary

Syros Pharmaceuticals (SYRS) will participate in two upcoming investor conferences to discuss advancements in the treatment of hematologic malignancies. The company's management will engage in a fireside chat at the JMP Securities 2024 Life Sciences Conference on May 14 and the TD Cowen’s 5th Annual Oncology Innovation Summit on May 29. Interested parties can access webcasts and archived recordings of the events on the Syros website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will report its first quarter 2024 financial results on Tuesday, May 14, 2024, with a live conference call and webcast scheduled. The company aims to advance new standards of care for hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
Rhea-AI Summary
Syros Pharmaceuticals receives Fast Track Designation from FDA for tamibarotene in combination with azacitidine and venetoclax for newly diagnosed AML patients with RARA overexpression. Positive results from SELECT-AML-1 trial show 100% CR/CRi rate with no added toxicity, potentially offering a new frontline treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
-
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ:SYRS) granted 8,400 shares of restricted stock units to a new employee as an inducement for employment. The RSU award vests over several years, subject to continued service with Syros.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
none
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) completes enrollment of 190 patients for primary endpoint analysis in SELECT-MDS-1 Phase 3 Trial, with pivotal CR data expected by mid-4Q 2024. Additional data from SELECT-AML-1 Phase 2 Trial also anticipated in 2024. The company completed a $45.0 million equity offering, extending cash runway into 2Q 2025. Management to host a conference call today at 8:30 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
-
Rhea-AI Summary
Syros Pharmaceuticals completes enrollment of 190 patients in Phase 3 clinical trial for tamibarotene in HR-MDS patients with RARA gene overexpression, on track to report pivotal data by mid-4Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) to report Q4 and full year 2023 financial results and host conference call on March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
Rhea-AI Summary
Syros Pharmaceuticals CEO to Participate in Panel Discussion at TD Cowen 44th Annual Health Care Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences

FAQ

What does Syros Pharmaceuticals specialize in?

Syros Pharmaceuticals specializes in mapping gene regulatory circuits and modulating factors that control gene expression to treat diseases.

What is unique about Syros Pharmaceuticals' approach?

Syros utilizes a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to decode gene regulation for therapeutic development.

In which therapeutic areas has Syros Pharmaceuticals shown success?

Syros has demonstrated success primarily in oncology, addressing unmet medical needs in hematologic malignancies.

What recent achievements has Syros Pharmaceuticals made?

Syros has continued to advance its clinical pipeline and establish strategic partnerships to drive innovation in gene control research.

What is the financial condition of Syros Pharmaceuticals?

Syros is well-funded and strategically positioned to continue its extensive research and development efforts in precision medicine.

What is the proprietary platform of Syros Pharmaceuticals?

It is a combination of assay technologies, bioinformatics, and biological insights developed to understand and modulate gene regulation.

How does Syros Pharmaceuticals impact patient treatment?

Syros develops new standards of care for frontline treatment, particularly for patients with hematologic malignancies, aiming to improve patient outcomes.

Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?

Syros is making its mark by leveraging its gene control research to develop innovative therapies, especially in oncology.

Who are the key contributors to Syros Pharmaceuticals' proprietary platform?

The platform has been developed by the experienced senior leadership team at Syros, integrating their expertise in disease biology and genomics.

What is the mission of Syros Pharmaceuticals?

The mission of Syros Pharmaceuticals is to transform the treatment of diseases by harnessing the power of gene control research to develop innovative therapies.

Syros Pharmaceuticals, Inc.

Nasdaq:SYRS

SYRS Rankings

SYRS Stock Data

142.73M
11.26M
1.08%
81.44%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE